OSE Immunotherapeutics
Clinical-stage biotech developing immune therapies for oncology and inflammation.
OSE | PA
Overview
Corporate Details
- ISIN(s):
- FR0012127173 (+2 more)
- LEI:
- 969500HIUWVGY6NZSM05
- Country:
- France
- Address:
- 22 BOULEVARD BENONI GOULLIN, 44200 NANTES
- Sector:
- Manufacturing
Description
OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering first-in-class therapies that control the immune system. The company's pipeline is concentrated in two key areas: immuno-oncology (IO) and immuno-inflammation (I&I). In immuno-oncology, its research aims to help the immune system recognize and target tumors. In immuno-inflammation, it develops treatments for autoimmune diseases and chronic inflammation by regulating immune responses. OSE Immunotherapeutics utilizes proprietary drug discovery platforms to generate novel product candidates, including monoclonal antibodies and RNA therapeutics, and collaborates with pharmaceutical partners to advance its assets through clinical development.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-03-11 18:00 |
OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for …
|
English | 246.4 KB | ||
| 2025-03-06 18:00 |
Informations relatives au nombre total de droits de vote et d’actions composant…
|
French | 193.7 KB | ||
| 2025-03-06 18:00 |
OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Fut…
|
English | 164.9 KB | ||
| 2025-03-06 18:00 |
Webinaire post-ECCO d’OSE Immunotherapeutics Lusvertikimab dans le paysage th…
|
French | 242.7 KB | ||
| 2025-01-13 18:00 |
OSE Immunotherapeutics annonce la nomination du Dr. Sonya Montgomery au poste d…
|
French | 218.6 KB | ||
| 2025-01-13 18:00 |
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Offic…
|
English | 222.2 KB | ||
| 2025-01-06 18:00 |
Ose Immunotherapeutics : Informations relatives au nombre total de droits de vo…
|
French | 199.5 KB | ||
| 2024-12-18 18:00 |
OSE Immunotherapeutics présentera les résultats d’induction de Phase 2 de l’an…
|
French | 309.1 KB | ||
| 2024-12-18 18:00 |
OSE Immunotherapeutics to Present Anti-IL-7R Lusvertikimab Phase 2 Induction Re…
|
English | 325.3 KB | ||
| 2024-12-11 18:00 |
OSE Immunotherapeutics annonce des avancées cliniques positives de Tedopi®, son…
|
French | 249.0 KB | ||
| 2024-12-11 18:00 |
OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Prop…
|
English | 286.3 KB | ||
| 2024-12-04 18:00 |
OSE Immunotherapeutics : Informations Relatives au Nombre Total de Droits de Vo…
|
French | 195.8 KB | ||
| 2024-12-02 18:00 |
OSE Immunotherapeutics Renforce son Équipe de Direction et son Comité Exécutif
|
French | 250.6 KB | ||
| 2024-12-02 18:00 |
OSE Immunotherapeutics Strengthens Leadership and Executive Committee
|
English | 260.5 KB | ||
| 2024-11-04 18:00 |
Informations relatives au nombre total de droits de vote et d’actions composant…
|
French | 229.8 KB |
Automate Your Workflow. Get a real-time feed of all OSE Immunotherapeutics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for OSE Immunotherapeutics
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for OSE Immunotherapeutics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-06-19 | N/A | Other | Other | 10,000 | 35,700.00 EUR |
| 2024-06-17 | N/A | Other | Other | 10,000 | 35,800.00 EUR |
| 2024-06-17 | N/A | Other | Other | 10,000 | 35,700.00 EUR |
| 2024-06-13 | N/A | Other | Sell | 6,369 | 45,879.09 EUR |
| 2024-06-03 | N/A | Other | Sell | 40,000 | 314,512.00 EUR |
Peer Companies
